Business Context and Reporting Period
Alexandria Real Estate Equities, Inc. (ARE) is a life science REIT focused on developing, redeveloping, and operating collaborative "Megacampus" ecosystems in key innovation clusters. This Form 10-Q covers the quarterly period ended June 30, 2026. As of this date, the company reported a total market capitalization of $21.84 billion, with an asset base comprising 36.0 million rentable square feet (RSF) of operating properties and 2.8 million RSF under construction.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $662.8 million | $1.33 billion |
| Net Income (Loss) Attributable to Common Stockholders | $(73.7) million | $286.7 million |
| Diluted EPS | $(0.43) | $1.68 |
| Funds From Operations (FFO) per Share (Diluted, as Adjusted) | $1.73 | $3.46 |
| Net Cash Provided by Operating Activities | N/A | $533.6 million |
| Total Debt (Unsecured Notes + Line of Credit/CP) | $12.81 billion | $12.81 billion |
| Liquidity (Cash + Line Availability) | $3.60 billion | $3.60 billion |
| Operating Occupancy | 86.9% | 86.9% |
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 13.0% year-over-year for the three months ended June 30, 2026, primarily driven by a 12.1% drop in rental revenues. This was caused by lower occupancy (87.1% vs. 92.6% prior year) due to key lease expirations and dispositions of non-core assets.
- Net Income Volatility: The company reported a net loss of $73.7 million for the quarter, compared to a loss of $109.6 million in the prior year. However, the six-month period showed a net income of $286.7 million, significantly improved from a loss of $121.2 million in the prior year. This improvement was largely driven by a $366.4 million gain on early extinguishment of debt recognized in February 2026 following tender offers.
- Impairment Charges: Real estate impairment charges increased to $222.5 million for the quarter (vs. $129.6 million prior year) and $228.0 million for the six months (vs. $161.8 million prior year). These charges relate to assets classified as held for sale in Greater Boston, San Diego, San Francisco Bay Area, and Canada.
- Investment Income: Investment income surged to $133.2 million for the quarter (vs. a loss of $30.6 million prior year), driven by $131.9 million in unrealized gains on non-real estate investments.
Guidance, Outlook, and Risks
- 2026 Guidance Update: Management narrowed the full-year 2026 FFO per share (diluted, as adjusted) guidance range to $6.35 – $6.45 (midpoint $6.40), maintaining the previous midpoint. The range narrowing reflects increased visibility into dispositions and capital sources.
- Capital Plan: The company expects to generate $2.10 billion to $3.70 billion (midpoint $2.90 billion) from dispositions, sales of partial interests, and other capital sources in 2026. These proceeds are intended to fund construction ($1.75 billion midpoint) and reduce unsecured senior debt by approximately $1.68 billion.
- Market Headwinds: The outlook cites significant challenges including an influx of new life science supply, reduced tenant demand, and a prolonged biotech bear market. These factors have led to elevated vacancy rates and downward pressure on rental rates, with same-property NOI declining 10.6% for the quarter.
- Legal Proceedings: The company is facing a securities class action filed in November 2025 and derivative actions filed in 2026 alleging misrepresentations regarding business performance and impairment charges. Additionally, litigation continues regarding the "Option Parcel" at the New York City campus, with potential losses ranging up to $183 million.
- Debt Management: In July 2026, the company amended its $5.0 billion unsecured senior line of credit, extending the maturity to 2032 and reducing the borrowing rate. The weighted-average remaining debt term is 9.7 years.
Investor Verification Checklist
- Disposition Execution: Verify the ability to close the projected $2.9 billion in asset sales given current market liquidity and valuation pressures.
- Occupancy Trends: Monitor the re-leasing of 451,450 RSF of key lease expirations expected in 2026 and 1.4 million RSF in 2027, which are projected to have 12–24 months of downtime.
- Impairment Risks: Assess the potential for additional impairments on the $555.8 million of assets currently classified as held for sale if market conditions deteriorate further.
- Legal Exposure: Track the resolution of the securities class action and the New York City Option Parcel litigation, which could impact financial results and capital allocation.
- Construction Spending: Confirm that construction spending remains aligned with the $1.75 billion guidance midpoint, particularly regarding the five projects currently under business strategy evaluation.